Dose-escalation Study of Oral CX-4945

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Cylene Pharmaceuticals
Study ID
NCT00891280
Phase
PHASE1
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CX-4945 oral formulation — DRUG
    CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.

Study Details

This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.

Key Dates

Start date
Feb 28, 2009
Status verified
Jun 2011
Primary completion
Dec 31, 2011
Completion
Dec 31, 2011

Study Design

Enrollment
55 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Safety (Dose limiting toxicities, maximum tolerated dose) [ Time Frame: One year (Assessed at Cycle 1) ]

Locations (4)

FacilityCityStateZIPSite coordinators
Mayo Clinic ArizonaScottsdaleArizona85259
Clinical Trials Office Mayo Clinic Cancer Center
507-538-7623
Donald Northfelt, MD (PRINCIPAL_INVESTIGATOR)
Front Range Cancer SpecialistsFort CollinsColorado80528
P. Zeller
970-212-7609
Robert F Marschke, MD (PRINCIPAL_INVESTIGATOR)
Front Range Cancer SpecialistsLovelandColorado80528
Pat Zeller
970-212-7609
R. McFarland, MD (PRINCIPAL_INVESTIGATOR)
U T M D Anderson Cancer CenterHoustonTexas77030
R. Alvarez, MD
[email protected]
R. Alvarez, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Scottsdale, AZ

By condition
Breast cancerMultiple myeloma
By specialty
OncologyBreast oncologyWomen's healthBlood cancer
By research site
Mayo Clinic Arizona· Scottsdale, AZFront Range Cancer Specialists· Fort Collins, COFront Range Cancer Specialists· Loveland, COU T M D Anderson Cancer Center· Houston, TX

Related Studies